Novo Nordisk A/S (NOVO-B.CO)
ValueMarkers Composite Index
16% below intrinsic value ($45)
Novo Nordisk A/S (NOVO-B.CO) — VMCI valuation read
Headline read on NOVO-B.CO: VMCI of 60/100 versus a Healthcare sector median of 50. The 10-point above-median position is what makes Novo Nordisk A/S a relative-value candidate in the mid-cap cohort, before any pillar-level review.
Form 4 filings on NOVO-B.CO: zero in the trailing 30 days. The absence of insider transactions is itself a data point, just a low-information one. The thesis runs on financials and price action until that changes.
**Investor frame.** Three reads on NOVO-B.CO: value (NOVO-B.CO trades at 23.0x earnings, 28% above the Healthcare median of 18.0x), quality (ROIC of 19.0% sits 9.0pp above the Healthcare median (10.0%)), and risk (net debt to EBITDA of 3.1x is the binding constraint on the bear case). The value read also implies an EV/EBITDA gap of +4.0x against the Healthcare 12.0x baseline.
NOVO-B.CO rose 3.0% over the trailing 7 days, with a +1.4% read on a 30-day basis.
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Rare Disease. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, glucagon, needles, and other chronic diseases. The Rare Disease segment offers products in the areas of haemophilia, blood disorders, endocrine disorders, growth disorders, and hormone replacement therapy. The company has a collaboration agreement with Gilead Sciences, Inc.; and research collaboration with Novo Nordisk to discover cell-specific carriers of nucleic acid therapeutics. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Related Stocks in Healthcare
Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.